Objective: Because epidemiologic data indicate a reduction in ovarian cancer risk with increased parity, the occurrence of maternal immunization against ovarian tumor-associated antigens during pregnancy was investigated.
Methods: Sera were obtained from nulligravid and multiparous women and from men. Cellular proteins were isolated from four ovarian tumor cell lines as well as from normal ovaries. These proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the presence of cellular proteins reactive with each individual's serum was assessed by Westrn immunoblot. Tumor-reactive antibodies from two multiparous women were used to prepare immunoaffinity columns for the isolation of reactive proteins from ovarian turmor cells. These immunoaffinity-purified antigens were transferred electrophoretically to nitrocellulose membranes, stained with Ponceau S, and identified by amino acid sequencing.
Results: Western immunoblot analysis of the cellular proteins from four established ovarian tumor cell lines using sera from multiparous women as the primary antibody indicated that these samples recognized multiple bands on ovarian tumors, ranging from 30 to 150 kD. Two commonly recognized proteins were isolated and subjected to microsequencing, which identified the 56-kD band protein as elongation factor-1α and the 38-kD protein as nucleophosmin/B23 protein. Both of these proteins play integral roles in cell growth.
Conclusion: These findings suggest that certain antigens expressed by the fetus immunize women during pregnancy. This immune response may protect these women from the subsequent development of cancer.
1. Patel AR, Obrams GI. Epidemiology of ovarian cancer. Cancer Epidemiol Biomarkers Prev1993;2:79-83.
2.
2. Perez RP, Godwin AK, Hamilton TC, Ozols RF. Ovarian cancer biology [Review]. Semin Oncol1991;18:186-204.
3.
3. Janerich DT. The fetal antigen hypothesis for breast cancer, revisited. Med Hypotheses1994;43:105-110.
4.
4. Polednak AP, Janerich DT. Characteristics of first pregnancy in relation to early breast cancer. J Reprod Med1983;28:314-318.
5.
5. Janerich DT. The influence of pregnancy on breast cancer risk. Med Hypotheses1980;6:1149-1155.
6.
6. Agrawal B, Reddish MA, Krantz MJ, Longenecker BM. Does pregnancy immunize against breast cancer?Cancer Res1995;55:2257-2261.
7.
7. Burchell J, Gendler S, Taylor-Papadimitriou J, et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res1987;47:5476-5482.
8.
8. Taylor DD, Doellgast GJ. Quantitation of peroxidase-antibody binding to membrane fragments using column chromatography. Anal Biochem1979;98:53-59.
9.
9. Taylor DD, Homesley HD, Dellgast GJ. “Membrane-associated” immunoglobulins in cyst and ascites fluids of ovarian cancer patients. Am J Reprod Immunol1983;3:7-11.
10.
10. Taylor DD, Homesley HD, Doellgast GJ. Identification of antigenic components recognized by “membrane bound” antibodies from ovarian cancer patients. Am J Reprod Immunol1984;6:179-184.
11.
11. Old LJ. Cancer immunology: The search for specificity—G. H. A. Clowes Memorial Lecture. Cancer Res1981;41:361-375.
12.
12. Taylor DD, Black PH. Shedding of plasma membrane fragments: Neoplastic and developmental importance. Dev Biol1986;3:33-57.
13.
13. Hellstrom KE, Hellstrom I. Principles of tumor immunity: tumor antigens. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer. New York: Lippincott, 1991:35-52.
14.
14. Volk DR, Scalise D, Schwartz DR, et al. Incidence of serum antibody reactivity to autologous head and neck cancer cell lines and augmentation of antibody reactivity following acid dissociation and ultrafiltration. Cancer Res1989;49:1361-1365.
15.
15. Owens K, Gercel-Taylor C, Taylor DD, Day TG, Doering DL. Isolation and characterization of an ovarian carcinoma cell line as a model for drug resistance. Proc Am Assoc Cancer Res1993;34:26-26.
16.
16. Testa JR, Getts LA, Salazar H, et al. Spontaneous transformation of rat overian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res1994;54:2778-2784.
17.
17. Brown R, Clugston C, Burns P, et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer1993;5:678-684.
18.
18. Laemmli UK. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature1970;227:680-685.
19.
19. Lui M, Tempst P, Erdjument-Bromage H. Methodical analysis of protein-nitrocellulose-m interactions to design a refined digestion protocol. Anal Biochem1996;241:156-166.
20.
20. Forsman LM, Jouppila PI, Andersson LC. Sera from multiparous women contain antibodies mediating cytotoxicity against breast carcinoma cells. Scand J Immunol1984;19:135-139.
21.
21. Gendler S, Taylor-Popadimitriou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelia mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem1988;263:12820-12823.
22.
22. Heller R, Fisher R, Nash A, Knapp J. Lack of relationship between parity and level of carcinoembryonic antigen in women with breast cancer. Anticancer Res1990;10:1755-1757.
23.
23. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelia mucin core peptides. J Immunol1993;151:3693-3703.
24.
24. Jacobson HI, Thompson WD, Janerich DT. Multiple births and maternal risk of breast cancer. Am J Epidemiol1989;129:865-873.
25.
25. Tatsuka M, Mitsui H, Wada M, Nagata A, Nojima H, Okayama H. Elongation factor-1 alpha gene determines susceptibility to transformation. Nature1992;359:333-336.
26.
26. Grant A, Flomen R, Tizard M, Grant D. Differential screening of a human pancreatic adenocarcinoma lambda gt11 expression library has identified increased transcription of elongation factor EF-1 alpha in tumour cells. Int J Cancer1992;50:740-745.
27.
27. Sonenberg N. Translational factors as effectors of cell growth and tumorigenesis. Curr Opin Cell Biol1993;5:955-960.
28.
28. Sorokine I, Ben-Mahrez K, Bracone A, et al. Presence of circulating anti-c-myb oncogene product in human sera. Int J Cancer1991;47:665-669.
29.
29. Kotera Y, Fontenot D, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res1994;54:2856-2860.
30.
30. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res1992;52:4168-4174.
31.
31. Mayordomo JI, Loftus DJ, Sakamoto H, et al. Therapy of murine tumors with p53 wild-type mutant sequence peptide-based vaccines. J Exp Med1996;183:1357-1365.
32.
32. Nozawa Y, Van Belzen N, Van der Made A, Dinjens W, Bosman F. Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol1996;178:48-52.
33.
33. Herrera J. Savkur R, Olson M. The ribonuclease activity of nucleolar protein B23. Nucleic Acids Res1995;23:3974-3979.
34.
34. Finch R, Chan P. Studies of actinomycin D induced B23-translocation in P388D1 cells implanted in DBA/2 mice. Oncology1992;49:223-226.
35.
35. Wang D, Umekawa H, Olson M. Expression and subcellular locations of two forms of nucleolar protein B23 in rat tissues and cells. Cell Mol Biol Res1993;39:33-42.
36.
36. Imai H, Kiyosawa K, Chan EK, Tan EM. Autoantibodies in viral hepatitis-related hepatocellular carcinoma. Intervirology1993;35:73-85.
37.
37. Ocbs RL, Stein TW, Chan EK, Ruutu M, Tan EM. CDNA cloning and characterizaiton of a novel nucleolar protein. Mol Biol Cell1996;7:1015-1024.
